Short answer
Colgate-Palmolive (CL) filed its fiscal 2025 10-K annual report with the SEC on Feb 23, 2026. It reported revenue of $20.4B (+1.4% year over year) and net income of $2.1B.
- Top risk flagged: FDA and global regulators reviewing fluoride, titanium dioxide, synthetic colors, and PFAS in consumer products: reformulation or restriction could materially impact core product lines
FY2025 key financial metrics · XBRL
- Revenue
- $20.4B
- +1.4% YoY
- Net income
- $2.1B
- −26.2% YoY
- Operating margin
- 16.2%
- −5.0 pp YoY
- Gross margin
- 60.1%
- −0.4 pp YoY
- EPS (diluted)
- $2.63
- −25.1% YoY
- ROE
- 3948.1%
- +2585.4 pp YoY
- Operating cash flow
- $4.2B
- +2.2% YoY
Source: XBRL data from the Colgate-Palmolive (CL) FY2025 10-K on SEC EDGAR. USD.
Colgate-Palmolive FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Two-segment model: Oral/Personal/Home Care (77% combined net sales) and Pet Nutrition (23%), sold in 200+ countries
- New C-suite hires: Shane Grant (COO Americas, ex-Danone) and John Hazlin (Chief Growth Officer) added in 2025
- Explicit strategic emphasis on AI, social commerce, and omni-channel demand generation as growth drivers vs prior year
- ~33,600 employees across 100+ countries; 84% outside the US, with Asia Pacific (33%) and Latin America (31%) as largest regions
- Colgate owns "world's most penetrated brand": household penetration cited as a core KPI of 2030 business strategy
Management Discussion & Analysis
- Revenue $20,382 in 2025, up 1.4% YoY; organic sales +1.4% driven by 2.1% net pricing, offset by -0.4% volume and -0.3% FX
- GAAP operating margin 16.2% vs 21.2% (−500 bps) due to $919 pretax Filorga impairment; non-GAAP operating margin 21.3% vs 21.7% (−40 bps); gross margin 60.1% vs 60.5%
- Best segment: Hill's Pet Nutrition, operating margin 23.1% vs 21.5% (+160 bps), revenue +2.9% to $4,613; worst: North America, revenue −1.6% to $4,045, operating margin 19.4% vs 20.4% (−100 bps)
- Operating cash flow $4,198 (+2% YoY); capex $564; dividends $1,823 ($2.06/share); share buybacks $1,210 (13.7M shares); new $5B repurchase program authorized March 2025
- Management expects 2025 category softness to persist into 2026; key risks include tariff-driven cost inflation, FX volatility, China weakness, and private-label trade-down; new Strategic Growth and Productivity Program targets $200–$300 pretax charges through 2028
Risk Factors
- FDA and global regulators reviewing fluoride, titanium dioxide, synthetic colors, and PFAS in consumer products: reformulation or restriction could materially impact core product lines
- Eurasia operations ~1% of consolidated net sales and ~2% of consolidated operating profit; cash repatriation from Russia blocked and financial institution access constrained
- Single-source or limited-supplier dependencies for key raw/packaging materials; new supplier qualification requires significant time and capital investment
- eCommerce and AI enabling direct-to-consumer competitors; key retailers leveraging AI-aided pricing algorithms and first-party data to pressure Colgate's shelf access and margins
- Q4 2025 non-cash after-tax impairment charge of $794M on skin health business goodwill and intangible assets, signaling acquisition integration risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.